Committed to patients with this serious hematologic disease
Beta thalassemia is a genetic blood disorder marked the inability to produce red blood cells that develop properly. Red blood cells are critical for tasks such as delivering oxygen to cells throughout the body. In people with beta thalassemia, low levels of hemoglobin lead to a lack of oxygen in many parts of the body.
Beta Thalassemia Symptoms & Complications
Affected individuals also have a shortage of red blood cells (anemia), which can cause pale skin, weakness, fatigue, and more serious complications such as enlarged livers and spleens. People with beta thalassemia are at an increased risk of developing abnormal blood clots.
Where is Beta Thalassemia Most Common?
Beta thalassemia occurs most frequently in people from Mediterranean countries, North Africa, the Middle East, India, Central Asia, and Southeast Asia.1
The Celgene Patient Commitment
Celgene has a rich heritage in discovering and developing therapies for serious blood disorders and cancers and is committed, alongside its partner Acceleron Pharma, Inc., to an investigational program for patients in this important area.
Advocacy & Collaboration
Celgene currently has an investigational therapy in clinical studies for patients with beta-thalassemia.
Visit BolderScience.com to learn more about the latest research in beta thalassemia:
Bolder Science: Beta Thalassemia